- Antibiotics Unveiled as Potential Life Extenders Aiding Healthier Aging
- NK Cells: Unveiling a Multifaceted Medical Marvel for Stroke Recovery and Beyond
- Japan’s Shift to Regular COVID-19 Vaccination for Elderly
- Active Monitoring vs. Surgery for Moderate Cervical Lesions
- Probiotics Linked to Immune Suppression and Tumor Growth
- FDA Investigates T-Cell Malignancy Risk in CAR-T Cell Therapy
China’s recombinant COVID-19 vaccine launches Phase III clinical trial in Uzbekistan
China’s recombinant COVID-19 vaccine launches Phase III clinical trial in Uzbekistan. According to the official website of the Chinese Embassy in Uzbekistan, on December 10, China’s domestically produced COVID-19 vaccine Anhui Zhifeilongkoma Biopharmaceutical Company’s international clinical phase III trial of recombinant new coronavirus vaccine was launched in Uzbekistan.
Jiang Yan, the ambassador to Uzbekistan, said that China and Uzbekistan have watched and helped each other during the epidemic and carried out effective anti-epidemic cooperation. The Phase III clinical trial of the vaccine in Uzbekistan is another major achievement of the cooperation between China and Uzbekistan in the field of anti-epidemic and biomedicine. It reflects the high level of the comprehensive strategic partnership between China and Uzbekistan. Connotation of “Road” cooperation. The current global situation of the COVID-19 epidemic is still severe, and China-Uzbekistan anti-epidemic cooperation still has a long way to go. I hope that this vaccine will be successfully tested and become a powerful weapon to defeat the epidemic and benefit the people of Uzbekistan and other countries.
Uzbekistan is the first country where China has launched a phase III clinical trial of a recombinant COVID-19 vaccine. Uzbekistan’s Deputy Prime Minister Musayev said that the Uzbek government will provide necessary guarantees for the smooth progress of the test, and believes that Uzbekistan-China vaccine cooperation will achieve fruitful results and help the two peoples overcome the difficulties together.
Gao Fu, director of the Chinese Center for Disease Control and Prevention and academician of the Chinese Academy of Sciences, said in a video speech that the world is currently looking forward to a safe, effective and long-lasting protective vaccine. It is hoped that the recombinant COVID-19 vaccine can become one of the best options and help the international community as soon as possible Control the epidemic and restore economic and social development.
It is reported that the recombinant COVID-19 vaccine jointly developed by the Institute of Microbiology of the Chinese Academy of Sciences and Anhui Zhifeilongkoma Biopharmaceutical Co., Ltd. started a phase III clinical trial in China on November 18 this year. Uzbekistan is the first overseas clinical trial site for this vaccine. According to the plan, 5,000 volunteers will participate in the trial.
According to Zhao Lijian, spokesperson of the Chinese Ministry of Foreign Affairs, on November 18, China has five COVID-19 pneumonia vaccines in the United Arab Emirates, Brazil, Pakistan, Peru and other countries to carry out phase III clinical trials, and many other vaccines are stepping up the clinical trials of phase I and II. test. On December 9, the UAE Ministry of Health and Prevention announced that it had officially registered the COVID-19 inactivated vaccine developed by China National Pharmaceutical Group. The UAE Ministry of Health and Prevention said in a statement that this is a major vote of confidence in the safety and effectiveness of the vaccine by the UAE government.